Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors.
Liu
Rebecca
R
The Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA. rebecca.liu@duke.edu
Mitchell
Duane A
DA
D000328:Adult; D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D017209:Apoptosis / Q000235:genetics / Q000276:immunology; D001932:Brain Neoplasms / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051034:Inhibitor of Apoptosis Proteins; D051379:Mice; D008869:Microtubule-Associated Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000276:immunology / Q000628:therapy; D000077022:Survivin
D000951:Antigens, Neoplasm; C107489:BIRC5 protein, human; D019496:Cancer Vaccines; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin